|
Fundamental approach in the management of Drava Bahula Amlapitta with Bhringaraja (Eclipta alba)
Hemant Pol1, Sharda More2, Mahesh Kumar Vyas3, Hitesh Vyas4, B Ravishankar5
1 Lecturer, Department of Samhita, Shubhdeep Ayurved Medical College and Hospital, Khandwa Road, Indore, M.P., India
2 Lecturer, Department of Agada Tantra, Shubhdeep Ayurved Medical College and Hospital, Khandwa Road, Indore, M.P., India
3 Associate Professor, Department of Basic Principles, Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, Gujarat, India
4 Assistant Professor, Department of Basic Principles, Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, Gujarat, India
5 Director, Research and Development, SDM Research Centre for Ayurveda and Allied Sciences, Udupi, Karnataka, India
Correspondence Address:
Hemant Pol
C/O Mr. Hanumantrao More, 'Shreevaibhav', Plot no.7, Lokmangal Co-op Hsg.Soc., opp. Hotel Kashmir (Bageecha) Dhaba, Padegaon, Aurangabad - 431005, Maharashtra
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0974-8520.96125
|
|
The disease Amlapitta has been selected for the clinical trials because it presents two type of manifestations depending upon the involvement of Agni (Ushnagunadhikya) and Jala (Dravagunadhikya) Mahabhuta. The present research work was focused at Drava Guna, with an aim to assess the efficacy of a drug with quality of Ruksha and Ushna predominance like Bhringaraja in treating Amlapitta with Pitta Drava Guna Vriddhi. Randomized open clinical trials were conducted on 22 patients of Amlapitta who were screened on the basis of clinical findings and allocated in to two groups. The criteria for selection were the signs and symptoms of Dravagunadhikya Amlapitta, irrespective of sex, religion, etc. Group A consisting of 15 cases received the trial drug Bhringaraja tablet (4 Tab. two times, 1 tablet=500 mg) and 7 cases in Group B received rice powder tablet as a placebo (4 Tab. two times, 1 tablet=500 mg) for 4 weeks. Special scoring pattern was adopted for the assessment of Amlapitta. Routine pathological tests such as blood, urine, stool, etc. were also carried out. In Group A, 55.33% patients showed marked improvement, whereas moderate improvement was observed in 26.67% patients. Complete cure was found in 06.67% of the patients and mild improvement in the chief complaints was observed in 13.33% patients. All the selected symptoms showed statistically significant results (P<0.01) except the Vidbheda in treated Group A, while in Group B, all symptoms showed statistically insignificant results except the Utklesha and Amlodgara. Total effect of the therapy showed statistically significant effect of the test drug . These results support the hypothesis. |
